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Detecting, quantifying, and discriminating the
mechanism of mosaic chromosomal aneuploidies
using MAD-seq
Yu Kong,1,4 Esther R. Berko,1,4,5 Anthony Marcketta,1,6 Shahina B. Maqbool,1
Claudia A. Simões-Pires,1,7 David F. Kronn,2 Kenny Q. Ye,3 Masako Suzuki,1
Adam Auton,1,8 and John M. Greally1
1Department of Genetics and Center for Epigenomics, Albert Einstein College of Medicine, New York, New York 10461, USA;
2Department of Pediatrics, New YorkMedical College, Valhalla, New York 10595, USA; 3Department of Epidemiology and Population
Health, Albert Einstein College of Medicine, New York, New York 10461, USA
Current approaches to detect and characterize mosaic chromosomal aneuploidy are limited by sensitivity, efficiency, cost,
or the need to culture cells. We describe the mosaic aneuploidy detection by massively parallel sequencing (MAD-seq) cap-
ture assay and the MADSEQ analytical approach that allow low (<10%) levels of mosaicism for chromosomal aneuploidy or
regional loss of heterozygosity to be detected, assigned to a meiotic or mitotic origin, and quantified as a proportion of the
cells in the sample. We show results from a multi-ethnic MAD-seq (meMAD-seq) capture design that works equally well in
populations of diverse racial and ethnic origins and how theMADSEQ analytical approach can be applied to exome or whole-
genome sequencing data, revealing previously unrecognized aneuploidy or copy number neutral loss of heterozygosity in
samples studied by the 1000Genomes Project, cell lines from public repositories, and one of the Illumina PlatinumGenomes
samples. We have made the meMAD-seq capture design andMADSEQ analytical software open for unrestricted use, with the
goal that they can be applied in clinical samples to allow new insights into the unrecognized prevalence of mosaic chromo-
somal aneuploidy in humans and its phenotypic associations.
[Supplemental material is available for this article.]
Somatic mosaicism occurs when a single population of cells
acquires a subpopulation with a different genotype. While mosai-
cism is an unavoidable consequence of the low level of background
mutation, making every multicellular organism a mosaic to some
degree, the pathogenic consequences of mosaicism are most ap-
parent when (1) it occurs early in development and therefore
affects a substantial proportion of cells forming one or more or-
gans, and (2) the genotypic alteration is a detrimental mutation.
Chromosomal abnormalities are found at surprisingly high
rates in human zygotes, with estimates that as many as three-quar-
ters of these early embryos contain aneuploid cells (van Echten-
Arends et al. 2011; Rabinowitz et al. 2012). It has been assumed
that there is a selective growth and survival advantage for any sub-
set of normal diploid cells contained within these embryos
(Bazrgar et al. 2013), accounting for the generally phenotypically
and chromosomally normal outcomes observed. It remains possi-
ble, however, that some of the aneuploid cells present in the zy-
gote persist through development. This is recognized more
frequently in placental than in embryonic tissues. When defined
by the presence of aneuploidy in chorionic villus sampling
(CVS) samples from the placenta, and the failure to detect such
aneuploid cells in fetal amniocytes or cells from the newborn, it
is referred to as confined placental mosaicism (CPM) (Lestou
and Kalousek 1998). With current technologies, approximately
0.8%–2.0% of all CVS specimens are found to have mosaic aneu-
ploidy, and a subset of 10%–20% of “confined” placental mosai-
cism is now recognized to have the same mosaic aneuploidy in
the fetus (Fryburg et al. 1993; Hahnemann and Vejerslev 1997;
Smith et al. 1999; Daniel et al. 2004; Lebo et al. 2015; Malvestiti
et al. 2015). CPM has been found at higher rates (up to ∼15%
[Wilkins-Haug et al. 2006]) in cases of intra-uterine growth restric-
tion (IUGR).
The prevalence of mosaic chromosomal aneuploidy is not
known to be substantial in humans, but it is almost certainly
underrecognized. The nature of the developmental event is such
that it may only affect an anatomically restricted group of cells
in the body, whereas routine genetic testing is almost always per-
formed upon DNA from peripheral blood leukocytes, looking for
constitutive, germline mutations. Blood is increasingly found to
have age-associated mosaic chromosomal aneuploidy (Jacobs
et al. 2012; Laurie et al. 2012; Schick et al. 2013; Machiela et al.
2015). Mosaicism for mutations, especially large structural vari-
ants, has been found to occur increasinglywith age in blood leuko-
cytes, reaching 2%–3% in individuals age 70 yr or older (Vattathil
and Scheet 2016). When cultured, blood is especially poor as a
choice of cells for detection of mosaic aneuploidy responsible for
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developmental disorders, exemplified by the failure to detect tet-
rasomy 12p in Pallister–Killian syndrome (Ballif et al. 2006;
Theisen et al. 2009; Hodge et al. 2012), with blood-derived lym-
phoblastoid cell lines (LCLs) likely to be even worse, given their
striking oligoclonality (Ryan et al. 2006). Current large-scale stud-
ies of human phenotypes, mostly based on blood or LCL DNA, are
therefore unlikely to be optimally sensitive for detection of the
presence of mosaic chromosomal aneuploidy. It follows that
even the studies to date involving thorough analyses of molecular
genomic data are likely to have systematically missed evidence
formosaic aneuploidy occurring in human subjects. In those stud-
ies in which mosaic chromosomal aneuploidy was specifically
sought, it was found to be associated with certain phenotypes,
including several reports of mosaicism for chromosomal aneuploi-
dy in peripheral blood in children with autism spectrum disorder
(ASD) (Abu-Amero et al. 2010; Chen et al. 2012; Kostanecka et al.
2012). Given the limitations of using blood to detect aneuploid
cells, it is likely that mosaic chromosomal aneuploidy in ASD
is not limited to these specific reported individuals but is more
prevalent.
Current technologies to detect and quantify mosaic chromo-
somal aneuploidy include karyotyping of chromosomes using
large numbers of metaphase cells generated using cell culture
(Kooper et al. 2009), fluorescence in situ hybridization (FISH) us-
ing probes detecting the aneuploid chromosome (Faggioli et al.
2014), microarrays to genotype the sample and measure the rela-
tive fluorescence of minor alleles (Conlin et al. 2010), single-cell
sequencing (Knouse et al. 2014), and whole-genome sequencing
(Dong et al. 2016). These approaches all have their relative
strengths, but we currently lack an assay that combines relative
ease and cost-effectiveness, sensitive detection of low proportions
of aneuploid cells, no requirement for cell culture, characterization
of the originalmitotic ormeiotic origin of themutation, suitability
for multiple racial and ethnic populations, and a supporting ana-
lytical software resource. To address this need, we developed the
MAD-seq assay and its supporting, open source MADSEQ analyti-
cal software package (see Supplemental Material).
Results
The MAD-seq capture assay
In a single sample of cells, chromosome aneuploidy is revealed by
altered dosages of minor alleles, usually referred to as alternate al-
lele frequencies (AAF), throughout a chromosome. For example,
normally an alternate (B) allele can be present at a diploid locus
at 0% (AA), 50% (AB), or 100% (BB) frequencies, but a cell with a
chromosome trisomy will have 0% (AAA), 33% (AAB), 67%
(ABB), or 100% (BBB) frequencies for that chromosome. Mosai-
cism for the trisomy in a population of otherwise diploid cells is re-
flected by values intermediate between these extremes, with the
proportion of mosaic cells reflected by the relative extent to which
the minor allele frequencies resemble the diploid pattern (indicat-
ing low-level mosaicism) or the trisomic pattern (indicating high-
level mosaicism). With greater numbers of loci representing each
chromosome, and more of these loci heterozygous in the individ-
ual tested, there will be greater ability to detect and quantifymosa-
ic aneuploidy in a cell sample from that person.
We therefore designed a trial customized SeqCap (Roche-
NimbleGen) assay (v1MAD-seq capture) that enriches the DNA
from 80,000 loci in the human genome, targeting loci with highly
polymorphic single nucleotide polymorphisms (SNPs). These
SNPs were selected based on being represented on the Illumina
HumanOmni2.5 genotyping array and having been studied by
the HapMap project (The International HapMap Consortium
2003) and by each having a minor allele population frequency of
at least 0.4 across the entire HapMap cohort. The 80,000 loci
were selected to be as equally spaced as possible throughout the
genome, using capture oligonucleotides designed by Roche-
NimbleGen, withmost loci having 1–3 tiling probes (mean length
75 nt, range 59–107 nt) for a 125-base pair (bp) window centered
around the interrogated SNP. Probes were successfully designed
to capture SNPs at 79,605 loci.
To test this capture system, we performed an experiment
simulating a variable proportion of alleles within a mixed sample.
We used cell line-derived DNA samples from a male Yoruban
(GM19239, Coriell Cell Repository) and a female Caucasian
(GM06990), mixing the DNA to create serial dilutions of
GM19239 in GM06990 in 50%, 25%, 10%, 5%, and 0.5% propor-
tions (Supplemental Table S1). A separate sample of GM06990 on
its own was prepared as a control (0%). Capture and Illumina se-
quencing were followed by alignment and processing using BWA
(v0.7.10) (Li and Durbin 2009), and elimination of PCR duplicates
using Picard (v1.119; https://broadinstitute.github.io/picard/).
Variant calling was performed using the Genome Analysis
Toolkit (v3.4–46) (McKenna et al. 2010), including base recalibra-
tion and variant calling using the HaplotypeCaller.We plotted the
dilutions of GM19239 inGM06990DNA against the proportion of
GM19239 to GM06990 alleles in Supplemental Figure S1a, show-
ing that the subset of GM19239 reads is clearly detectable down
to 5%.We therefore proceeded to develop further an analytical ap-
proach that would allow us to detect single chromosome aneuploi-
dy events following such capture.
The MADSEQ analytical approach
We provide an overview of the analytical approach in Figure 1.
There are two main components to MADSEQ—the processing
of the sequencing data and the generation and comparison
of hierarchical Bayesian models. The output of theMADSEQ anal-
ysis consists of (1) the identification of aneuploidy for one or
more chromosomes, (2) categorization of the type of aneuploidy,
(3) quantification of the fraction of cells with the aneuploidy,
and (4) a confidence metric in the results obtained.
We show simulated results for four types of chromosomal
mutations detected by the MADSEQ analytical approach in
Figure 2, monosomy, mitotic and meiotic trisomy, as well as
copy number neutral loss of heterozygosity (cnnLOH). The chro-
mosomal events underlying these results are represented in
Supplemental Figure S2. We include cnnLOH as it could represent
the consequence of trisomy rescue earlier in development (Bie-
secker and Spinner 2013) in currently diploid cells. However, we
developed the MADSEQ approach so that it could also detect seg-
mental LOH occurring in >10% of contiguous heterozygous sites
tested in each chromosome. What is apparent from Figure 2 is
that our ability to detect and discriminate the different types of an-
euploidy events depends upon the alternate allele frequencies in
combination with any deviation from the genome-wide average
coverage of sequence reads for that chromosome. For example,
while mosaic monosomy andmosaic mitotic trisomy have similar
alternate allele frequency patterns, they differ by coverage, with
trisomy generating an excess and monosomy a deficiency of se-
quence reads for that chromosome compared with the remainder
of the genome. A meiosis II nondisjunction causing trisomy will
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appear similar to trisomy caused by mitotic nondisjunction but
can be distinguished by the presence of a chromosomal region
that underwent recombination earlier in meiosis, which is flagged
in the MADSEQ analysis when choosing the optimal model.
Evaluation of MADSEQ performance
We tested the performance ofMADSEQ in two ways. The first eval-
uation was a re-analysis of the GM19239/GM06990mixing exper-
imental data, the second based on computational simulations. For
the Yoruban/Caucasian mixing experiment, we used a beta distri-
bution to fit the alternate allele frequency and measured the devi-
ation in these samples from an expected distribution in diploid
cells. We measured this deviation for each chromosome in each
of the samples and plotted the relationship between this distance
and the expected proportions of GM19239 DNA, as shown in
Supplemental Figure S1b. We showed the expected correlation
with the known mixture proportions but this time using our
AAF deviation distance, indicating that the model was able to re-
produce the information from known Yoruban and Caucasian ge-
notypic differences.
Wewent on to explore the sensitivity, specificity, and accura-
cy of theMADSEQ approach using computational simulations. To
assess sensitivity, the performance of the model was tested in
terms of sequencing depth, proportion of aneuploid cells present,
and the number of heterozygous sites sequenced per chromosome.
For example, if 2000 heterozygous sites on a chromosome are se-
quenced to 100× coverage, our model should be able to detect
5% mosaicism for meiotic trisomy with >99% sensitivity at a false
discovery rate (FDR) of <2% (Supplemental Fig. S3). The power to
detect lowproportions ofmosaic aneuploidy increases with deeper
sequencing and higher numbers of heterozygous sites sequenced.
When 2000 heterozygous sites are sequenced to 200× coverage, we
predict more than 50% power to detect all types of mosaic aneu-
ploidy occurring in 10% of cells. We also tested the conditions
of whole-genome sequencing (WGS), in which coverage is much
lower but the number of informative heterozygous sites per chro-
mosome is much higher. The results from these simulations indi-
cate that MADSEQ analysis of WGS data will detect aneuploidy
events even to low levels of mosaicism and in the smallest human
chromosomes (Supplemental Fig. S4).
Specificity issues and the generation of false positive results
are important for an assay that might be used for clinical diagnos-
tic purposes. We evaluated the FDR of our method by simulating
data without aneuploidy but with the simulated introduction of
noise in the sequencing data. We represented noise by replacing
the alternate allele frequencies of 10% of the heterozygous sites
with values distributed randomly between 0 and 1. The result
(Supplemental Fig. S5) suggests that our model is very robust,
with an overall FDR at <2%. The accuracy of the quantification
of the fraction of abnormal cells was assessed using the root-
mean-square-error (RMSE) calculated from computational simula-
tions. In Supplemental Figure S6, we show that the quantification
is accurate, with deviation from the expected proportion of less
than 10% for all the conditions tested, with accuracy increasing
with deeper coverage but with less effect from including more se-
quenced sites per chromosome.
Application of MADSEQ to sequencing data
We then explored whether analysis usingMADSEQ could identify
mosaic aneuploidies from publicly available sequencing data. The
1000 Genomes exome sequencing was generated to a mean of
65.7× coverage, potentially capable of discovering at least some
mosaic aneuploidy events if present in these samples. Of the
2535 individuals studied in the 1000 Genomes Project, 2037
were sequenced using DNA derived from LCLs, whereas the re-
maining 498 were sequenced from peripheral blood leukocyte
Figure 1. TheMADSEQ analytical approach has two major components: the processing of the sequence data (left); and the use of alternate allele distri-
butions and relative read depth to support a specific hierarchical Bayesian model (right). This model is based on fitting a mixture model of alternate allele
frequencies (AAFs) at heterozygous loci (showing the additional distributions in a situation of mosaic meiotic trisomy) and read depth for the affected chro-
mosome compared with the remainder of the genome. The winning model is selected by its significantly better Bayesian information criterion (BIC), gen-
erating an output of the presence and type of mosaic aneuploidy (or copy number neutral loss of heterozygosity), the proportion of cells with the
aneuploidy, and the confidence of this prediction based on relative BIC values.
Mosaic aneuploidy detection by sequencing: MAD-seq
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DNA. MADSEQ detected 83 mosaic events with high confidence
(ΔBIC > 10) in 76 individuals (Supplemental Table S2). All of
the detected mosaic aneuploidies were from LCL samples, and
none from blood. The types of mosaic aneuploidy include 20
monosomies (0.79%), 25 mitotic trisomies (0.99%), and 37 LOH
(1.46%), but no meiotic trisomies, even though the model is rela-
tivelymore sensitivewhen detectingmeiotic events. Of note, all of
the cases of LOH were segmental rather than involving the whole
chromosome, likely to represent the result of a repair of deletion
using the remaining homologous chromosome as a template
(O’Keefe et al. 2010), and not trisomy rescue.
The rate of these mosaic events among LCL samples was
3.73%. The proportions of aneuploid/segmental LOH cells in
each sample varied from4.2% to 79.9%. Themost overrepresented
events were mosaic mitotic trisomy of Chromosome 12 in 11 sam-
ples (P = 1.49 × 10−4, Binomial Test) and enrichment for mosaic
segmental LOH in Chromosome 22 (P = 7.14 × 10−3, Binomial
Test) (Supplemental Table S3).Overall, the significant lackofmosa-
ic aneuploidy events in samples from blood (P = 3.08 × 10−34,
Binomial Test) and the lack ofmeiotic events, togetherwith the en-
richmentof trisomy12,which is themost commoncytogenetic ab-
normality in chronic B lymphocytic leukemia (Einhorn et al.
1989), combine to suggest that these mosaic aneuploidies arose
during cell culture andwere either neutral in effect orwere promot-
ed by positive selection for these transformed B lymphocytes. One
of the samples in which segmental LOH for distal Chromosome 11
was identified was GM12889, for which whole-genome sequenc-
ing to a mean ∼50× coverage has been performed to define high-
confidence, “platinum”variants (Eberle et al. 2017).Wedownload-
ed thoseWGSdata and reranMADSEQ, againpredicting theLOHof
a 19.3-Mb region, estimated to be present in over 50% of the cells
(Fig. 3). The platinum variant calling in this part of the genome
in this individual shouldbe interpretedwith caution.Weshowrep-
resentative examples of plots of the alternate allele frequencies and
the comparisons of the Bayesian Information Content (ΔBIC) in
Supplemental Figure S7.
We then tested a sample from a patient presenting with
hemihyperplasia (OMIM 235000). The hyperplastic side of the
patient demonstrated a hyperpigmented whorl pattern, following
Blaschko’s lines. The Blaschko’s lines were only present on the hy-
perplastic side and did not cross the midline. Skin biopsies were
performed on the normal skin of the unaffected side and from
the hyperpigmented skin of the affected side. A microarray study
from DNA directly extracted from these biopsies showed evidence
for mosaic trisomy 12 from the affected side only. We grew fibro-
blasts from the remainder of the skin biopsy and extracted DNA
from these cultured cells, performing exome sequencing to a
mean 130× coverage. The MADSEQ model best fit by the results
was of mosaic trisomy ofmitotic origin present in 6.8% of the cells
(ΔBIC = 18) (Fig. 4). Trisomy 12 has also been found in human
Figure 2. Results of simulations of each of the types of aneuploidy (plus copy number neutral loss of heterozygosity, cnnLOH). Each plot on the left shows
the AAF distributions in steps of 10% proceeding from no aneuploidy (complete diploidy) to aneuploidy in all cells. On the right is shown the expected
change of sequencing depth for the affected chromosome. Because meiotic trisomy with recombination creates a non-recombined region with LOH
and a recombined area with three different haplotypes, two patterns are created within these chromosomes, the pattern in the recombined region being
very distinctive (top). The coverage for a trisomic chromosome is increased relative to others in the genome. Trisomy occurring in mitosis (or in meiosis
without recombination) generates a similar profile in terms of AAF to mosaic monosomy, but these events are distinguished by coverage being higher
for trisomy and lower for monosomy. Segmental cnnLOH is shown in the bottom panels, the affected area of the chromosome showing an AAF pattern
similar to monosomy but with no change in copy number. A region showing nonmosaic (100%) cnnLOH reflects consanguinuity, at a locus of identity
by descent.
Kong et al.
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AB
Figure 3. The GM12889 sample has been tested using exome sequencing as part of the 1000 Genomes study (A) and using whole-genome sequencing
to mean 50× coverage (B). The application of the MADSEQ approach shows the predictions for each chromosome and the differences in Bayesian infor-
mation criterion for each model. The top plot within each panel shows these BIC values for each model on the y-axis for each chromosome (x-axis). The
horizontal dashed line represents our threshold difference for discriminating between models. In A, we see that a cnnLOH model for Chromosome 11 is
strongly predicted, occurring in 58.7% of cells. Whole-genome sequencing data from the same DNA shows a highly concordant prediction of mosaicism
for segmental cnnLOH in the same region of distal Chromosome 11 (bottom) in 53.5% of cells.
Mosaic aneuploidy detection by sequencing: MAD-seq
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embryonic stem (ES) cell lines (Draper et al. 2004) and induced plu-
ripotent stem (iPS) cells (Taapken et al. 2011) and has been impli-
cated in the significant increase of their cellular proliferation rate
and tumorigenicity (Ben-David et al. 2014). The hemihyperplasia
phenotype may therefore be the consequence of a higher cell rep-
lication rate due to the presence of the mosaic subset of cells with
trisomy 12. Our categorization that this was a mosaic trisomy of
mitotic origin (Fig. 4) indicates that the nondisjunction and chro-
mosomal loss events occurred post-fertilization and are not due to
meiotic trisomy during gametogenesis with later trisomy rescue,
unless the rescue of a meiotic trisomy was compounded with the
additional event of no recombination during meiosis.
Development of a multi-ethnic MAD-seq (meMAD-seq) capture
assay design
To complement our exome sequencing results, we returned to our
v1MAD-seq capture design and tested its performance with six
samples, four of which were known to have autosomal trisomies,
and two control cell lines apparently lacking aneuploidies. Using
MADSEQ analysis of the results, we confirmed the four trisomies
(Chromosomes 8, 13, 15, or 18), mostly concordant with prior re-
ported proportions of trisomic cells, and defined their origins as
meiotic in all cases. One of the control cell lines (GM06990) that
had not previously been described to have aneuploidy was found
to have a pattern consistent with 6.6% of cells having monosomy
for Chromosome 6 (Table 1).
When we explored the performance of the v1MAD-seq cap-
ture and exome sequencing systems, we found that the representa-
tion of heterozygous sites on many of the smaller chromosomes
was highly suboptimal. The v1MAD-seq capture design spaced
loci for capture evenly throughout the genome, causing larger
chromosomes to have proportionately more informative loci
(Fig. 5A), while exome-seq is limited by the number of genes per
chromosome, which is a function of not only the chromosome
size but also its gene content. In Figure 5B, we show this heteroge-
neity of representation for each chromosome for exome sequenc-
ing data. Of particular concern was the poor representation of
informative loci for Chromosomes 13, 18, and 21, the most com-
mon viable full trisomies.
To create a design that is maximally efficient in sequencing
informative loci, with resulting efficiencies in assay cost, we creat-
ed a newmulti-ethnic MAD-seq capture design. A total of 107,797
(Roche NimbleGen Catalog No. 06740260001, Design Identifier:
160407_HG19_MadSeq_EZ_HX1) common SNPs were chosen to
represent each chromosome equally. We also exploited the 1000
Genomes data to identify loci that would bemost likely to be poly-
morphic across all human populations (Supplemental Fig. S8). We
show the workflow for the design of the meMAD-seq capture plat-
form in Supplemental Figure S9. This design captures 106,402 loci
in the human genome of mean length 139 bp and mean (G +C)
content 44.4%.
We tested the meMAD-seq capture design on 12 samples.
These included the six samples tested using the v1MAD-seq cap-
ture design, the HG01939 sample predicted to have two separate
chromosomeswith loss of heterozygosity fromour 1000Genomes
exome sequencing re-analysis, samples from the affected and
unaffected sides of the body of the individual with hemihyperpla-
sia, and two Coriell cell repository samples, one of which was de-
scribed to have mosaic trisomy 8 (GM00496), and a sample
described to have mosaic trisomy 12 as well as random chromo-
some rearrangements (NA01454), and DNA from the H1 human
embryonic stem cell line (Thomson et al. 1998). We show the re-
sults in Table 1 and Figure 5, confirming prior observations of
chromosomal aneuploidies or loss of heterozygosity fromCoriell’s
characterizations, our exome sequencing data re-analysis, or the
v1MAD-seq capture results, and adding information about wheth-
er each trisomy was likely to be meiotic or mitotic in origin.
Our 1000 Genomes SNP selection strategy was designed to
generate data from the same number of heterozygous sites for
Figure 4. The results of sequencing skin biopsy samples from each side of the body of a child with hemihyperplasia. Results from the normal side are
shown on the left and from the overgrown side on the right. Exome sequencing to ∼100×mean coverage indicates a model of mosaic trisomy 12 of mitotic
origin in 6.8% of cells, while the more targeted (multi-ethnic) meMAD-seq capture assay (described later) sequenced to a comparable depth shows ev-
idence for the same type of mosaicism in 5.4% of cells.
Kong et al.
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each chromosome and across all popula-
tions. Our goal was to exceed 1000 het-
erozygous sites per chromosome, but we
show in Figure 5C that we obtain ≥2000
heterozygous loci for every chromosome
across all individuals. In Supplemental
Figure S10, we show that the individuals
tested using the meMAD-seq capture de-
sign were indeed from widely divergent
human population groups. We con-
firmed mosaic aneuploidies in samples
known to have these abnormalities from
Coriell’s characterization or from our
prior studies. Two chromosomes with
segmental LOH predicted from our 1000
Genomes exome sequencing data ana-
lysis were confirmed in the HG01939
cell lineusing themeMAD-seq capture as-
say. Some of the supposedly normal con-
trol samples were also revealed to have
aneuploidy, including low level, previ-
ously unrecognized events in the ES cells
and the GM06990 female Caucasian
sample used in our initial serial dilution
experiments.
For a cost comparison, we deter-
mined the reagent cost expense associat-
ed with library preparation, capture, and
sequencing to comparable depth for the
more mainstream exome sequencing ap-
proach (SeqCap EZ, Roche-NimbleGen)
and the meMAD-seq capture alternative.
We estimate that, for each assay to gener-
ate a mean ∼110× coverage, the reagent
cost for meMAD- seq capture would be
∼40% of the cost for exome sequencing,
which should be a generalizable guide
for facilities with different costs.With in-
creased production of the meMAD-seq
capture kit, further cost savings may be
possible.
Discussion
This study further strengthens the con-
cern that mosaic aneuploidy is likely to
be underrecognized. The 1000 Genomes
Project performed extensive analysis
and quality assessment of their samples
and data (The 1000 Genomes Project
Consortium 2015), but even these care-
fully studied samples have mosaic aneu-
ploidy in several percent of the LCL
samples studied, estimated by MADSEQ
to involve as many as ∼80% of cells.
While we interpret the results to indicate
that these cases of mosaicism arose
during cell culture, this finding should
increase the caution requiredwhen inter-
preting information from LCLs in terms
of their representation of the donor’s
chromosomal status.
A
B
C
Figure 5. A performance comparison of v1MAD-seq capture (A), exome sequencing (B), andmeMAD-
seq capture (C) in terms of the number of heterozygous sites tested per chromosome. On the A, of each
plot is a representation of sequencing depth, on the B, the number of heterozygous sites per chromo-
some. On the left of each violin plot is the distribution in females (pink); on the right, males (blue), allow-
ing differentiation of patterns on the sex chromosomes. The v1MAD-seq capture platform spaced probes
evenly throughout the genome, generating more heterozygous sites in larger chromosomes despite
equivalent coverage. Exome sequencing (1000Genomes data) generates a number of heterozygous sites
that depend on chromosome size and gene density within the chromosome, so that the comparably
sized Chromosomes 18 and 19 differ because of the much greater gene content of the latter. There is
also an ancestry effect on heterozygosity rates, with African ancestry performing best and East Asian an-
cestry worst in generating heterozygous sites. The meMAD-seq capture design allows much more uni-
form performance of every chromosome in the genome, most exceeding 1500 heterozygous sites per
chromosome.
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We also find that reference cell lines that have been character-
ized using standard techniques have evidence for chromosomal
abnormalities. The human H1 ES cell line has previously been
found to develop trisomies in vitro (Draper et al. 2004), requiring
periodic testing to ensure that the cells being used experimentally
remain diploid. Reference cell lines supplied by repositories or used
in large studies also require careful characterization to ensure that
they are not undergoing alterations that could lead to issues of re-
producibility of results. It should be stressed that the poor repre-
sentation of certain chromosomes in exome sequencing data,
coupledwith someof the 1000Genomes samples having relatively
lower mean coverage, combine to indicate that we are probably
missing some further cases of mosaic aneuploidy. The systematic
application of MADSEQ analysis, allied with meMAD-seq capture
and sequencing, would probably reveal an even higher proportion
of reference cell lines with mosaicism.
The analytical software MADSEQ is open source, available
through Bioconductor (see SupplementalMaterial), and can be ap-
plied not only tomeMAD-seq capture data but also, as we show, to
exome sequencing and even whole-genome sequencing data. It
could therefore be applied retrospectively to legacy sequence
data to look for aneuploidy, generating preliminary results that
could then prompt the application of meMAD-seq capture for
more systematic studies. It appears that more development will
be needed to extend the use of MADSEQ to cancer samples.
When multiple chromosomes have abnormal copy numbers, de-
termining what coverage value represents diploidy becomes diffi-
cult, weakening a foundational component of the analysis. Our
NA01454 sample (Supplemental Fig. S7i) is not from a cancer
but has multiple chromosomes with abnormal patterns of AAFs
and copy numbers and helps to illustrate how the approach starts
to have difficulties when many chromosomes are affected. This
will be a focus of further algorithm development, but in the
short term,MADSEQ is valuable for detecting the presence of aneu-
ploidy in even these complex samples.With further development,
MADSEQ could also be used to detect mosaicism for copy number
variants (CNVs). However, the resolution of detection will differ
based on spacing of the captured heterozygous loci which, in the
meMAD-seq capture design, is higher for larger chromosomes,
with more physical clustering of captured loci in smaller chromo-
somes. The most appropriate future application of MADSEQ for
mosaic CNV identification may be fromWGS data.
Ideally, prospective studies will exploit existing WGS data
or the targeted sequencing option of meMAD-seq capture, allow-
ing optimal cost and performance. The meMAD-seq capture
design, which will be made publicly available through Roche-
NimbleGen, shows excellent performance not only in terms of
maximizing the number of informative sites per chromosome
but also testing each chromosome comparably. We were careful
to ensure that the design could be applied equally effectively to
people of widely differing ancestries, allowing it to be used world-
wide and in our local, highly diverse clinical population.
We anticipate several areas of human disease research that
would immediately benefit from MADSEQ. In prenatal genetics
care, screening is performed looking for chromosomal aneuploi-
dies, increasingly using noninvasive prenatal testing (NIPT) of
cell-free DNA in the maternal blood. Positive results from this
screening approach can be followed up with invasive tests of fetal
cells (chorionic villus sampling, amniocentesis), which can then,
in a proportion of cases, lead to discordance between aneuploid
NIPT and normal fetal chromosomal results. This discordance is
presumed to be due to confined placental mosaicism for the aneu-
ploidy, but this diagnosis can only be made with the certainty af-
forded by the sensitivity of the test used on the fetal cells. There is
potential for WGS or meMAD-seq capture and sequencing allied
withMADSEQ analysis to enhance the sensitivity of these diagnos-
tic studies. A second potential area worth exploring for covert an-
euploidy is in individuals with autism spectrum disorder.We have
noted in a prior study (Berko et al. 2014) the association between
advanced maternal age and the risk of having a child with ASD
(Sandin et al. 2012). The increased nondisjunction rate in oocytes
fromoldermothers suggests that chromosomal aneuploidy should
be tested as a possible mediator of this association, but at present,
there is little evidence for aneuploidy in individuals with ASD. A
more sensitive assay like meMAD-seq capture applied to samples
other than blood from individuals with ASD born to oldermothers
may be helpful in exploring a potential cause of this heteroge-
neous condition.
Sequencing data fromWGS or the meMAD-seq capture assay
combined with the MADSEQ analytical approach can be used on
uncultured cells, detects low levels of aneuploidy, identifies the
likelymechanism of the initial causative event, is relatively cost-ef-
ficient, and can be used in any ancestral background. It combines
manyof the advantages of existing assays to detect aneuploidy and
should be suitable for high-throughput studies. The eventual goal
should be to associate different types of mosaic chromosomal
events with human phenotypes.
Methods
Molecular assays
Cell line mixing experiments
DNA extracted from two individuals’ LCLs (GM06990, CEU, fe-
male and GM19239, YRI, male) was mixed at different propor-
tions, choosing 100%:0%, 99.5%:0.5%, 95%:5%, 90%:10%,
75%:25%, and 50%:50% to mimic different levels of mosaicism.
The DNA was sequenced following a capture protocol using the
SeqCap EZ Choice system from Roche-NimbleGen. The list of tar-
geted regions and probes used for the v1MAD-seq capture design
can be found in our dbGaP submission. Knowing the genotype
of both samples, wewere able to extract sites thatmimic the differ-
ent types of mosaic aneuploidy. Specifically, to simulate mitotic
aneuploidy, we first extracted loci with different genotypes in
the two cell lines, 0/1 in CEU and 1/1 in YRI to mimic overrepre-
sentation of the alternate allele, and 0/1 in CEU and 0/0 in YRI
tomimic underrepresentation of the alternate allele. The twomix-
tures separated further when a higher proportion of YRI DNA was
mixedwithCEUDNA (Supplemental Table S1). Because thesemix-
tures of DNA alter the distribution of alternate allele frequency
without changing the actual copy number of chromosomes, we
applied the model without the coverage module.
Exome sequencing of a patient with hemihyperplasia
DNA was extracted from fibroblasts cultured from skin biopsies
from the affected and unaffected sides of the body of a patient
with hemihyperplasia (OMIM 235000). We performed exome se-
quencing of the sample from the affected side of this patient using
the SeqCap EZ Exome Enrichment kit v3.0 (Roche-NimbleGen)
and 100-base pair paired-end sequencing on the Illumina HiSeq
2500 system. The average coverage was 142.1×.
Targeted sequencing
DNA was purchased from Coriell for the samples HG01939,
NA00682, and NA01454, and DNA was extracted from fibroblasts
Mosaic aneuploidy detection by sequencing: MAD-seq
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(AG13074, GM00496, and GM00503), LCLs (GM06990, GM19239)
buccal epithelial cells of one patient (F44P110), and a human em-
bryonic cell line (H1). DNA extracted from the normal and abnor-
mal cultured fibroblasts of the hemihypertrophy patient was also
included. We used the Roche NimbleGen SeqCap EZ Choice sys-
tem to capture the multi-ethnic design of the 105,703 common
SNPs described below. All of the samples were sequenced with
100-bp paired-end sequencing using the Illumina HiSeq 2500
(Illumina), generating an average coverage of 134.6×.
Sequencing depth correction
G+C content can vary in the genome and influence the number
of reads generated at each captured region, potentially introducing
bias into aneuploidy detection. We therefore used LOESS correc-
tion to correct in our package for such bias. Given the targeted
region and BAM file, the average coverage for each targeted region
(raw covi) is calculated by a coverage function from theMADSEQ R
package called GenomicAlignments. If more than one sample is
sequenced during the same capture protocol, quantile normaliza-
tion is first applied to the coverage across all samples. The G +C
content (gci) for each targeted region is then calculated as the
G +C percentage of the reference genome (excluding Ns).
Coverage for each targeted regionwas grouped by 0.1% increments
of G +C content, and the average coverage for each level of G +C
contentwas calculated. The scatterplot representing theG +C con-
tent plotted against the average coverage for each G +C level can
be produced as part of the MADSEQ pipeline (Supplemental Fig.
S11). The regression curve between coverage and G +C content
was fitted by LOESS. The GC content for the ith region is gci, the
fitted coverage for this region denoted as covgci . The expected
coverage (covexp) is set to the median of read depth across all re-
gions. The corrected coverage for the ith region (corrected covi) is
then calculated as
corrected covi = raw covi − (covgci − covexp)
Bayesian models
Our statistical model for detecting mosaic aneuploidy consists of
two parts. For each chromosome, we first consider the distribution
of the alternate allele frequencies at the heterozygous sites; second-
ly, we consider the distributionof sequencing depth at these loci. If
mosaic aneuploidy is present in the sample, we expect the distribu-
tion of both the alternate allele frequency and sequencing depth to
deviate from that expected in a simple diploid sample. Here, we
describe each part of the model separately:
1. Detection of aneuploidy from alternate allelic fractions.
The alternate allele fraction is the proportion of reads car-
rying the alternate allele at a given heterozygous site, calculated
as the alternate allelic depth divided by the total read depth. If
there is no aneuploidy in any of the sampled cells, then the
AAFs at heterozygous sites are expected to be centered around
0.5 (ignoring confounding biases such as reference bias)
(Castel et al. 2015). However, if a fraction of cells within the
sample are aneuploid, then the distribution of AAFs will deviate
from the expected midpoint and instead be better described by
amixture of distributions, where the number and parameters of
the mixture components depend on the origin of the aneuploi-
dy and the degree of mosaic aneuploidy.
1. Model0: diploid chromosome. For a normal, diploid chromo-
some state, the AAF at heterozygous sites is expected to be a
single distribution centered around the midpoint (average
AAF across all heterozygous sites). In this situation, wemodel
the alternate allelic depth (ADi) for biallelic heterozygous site
i as a simple beta-binomial distribution, given the read depth
for the ith site Ni
ADi  betabinomial(Ni,an = mk,bn = (1− m)k)
Here, α and β are determined by the prior μ and κ. μ de-
notes the midpoint, namely the average AAF across all the
heterozygous sites. κ represents the variance of the AAF.
We model κ as a gamma distribution
k  gamma shape = m
2
s2
, rate = m
s2
( )
In ourmodel, the larger the κ is, the smaller the variance
for the beta distribution. For the purpose of Bayesian infer-
ence, we assigned the prior for this gamma distribution as
m = 10, σ = 10 to represent a flat prior distribution.
To account for noise normally present in high-through-
put sequencing data, we added an additional outlier compo-
nent weighted as 1% (ω0 = 0.01; ωn + ωo = 1) of all
heterozygous reads. The outlier component is modeled by
a uniform beta-binomial distribution as
ADo  betabinomial(No,ao = 1, bo = 1)
If there are K heterozygous sites from one chromosome,
and mu and Kappa are constant for all n = 1,…K, the likeli-
hood of the data is then given by
P AD|N,a,b( ) = ∏K
i=1
(vndbetabinom(ADi,Ni,an,bn)
+ vodbetabinom(ADi,Ni,ao,bo))
where P(AD|N, α, β) are vectors of the parameters.
2. Model1: mosaicmonosomy.Mosaicmonosomy is the conse-
quence of the loss of one chromosome in a subset of cells. In
mosaic monosomy, the AAF separates from the midpoint
into twomixtures (Fig. 2). Onemixture is shifted toward low-
er values due to the overrepresentation of the reference allele,
and the other shifted toward higher values due to the over-
representation of the alternate allele. We assume that the
two mixtures have equal weight (ω1 = ω2 = 0.495) and vari-
ance (κ), with the same outlier component (ωo = 0.01) de-
scribed in model0; the allelic depth of heterozygous sites
can be modeled as
ADi  (v1betabinomial(Ni,a1 = m1k,b1 = (1− m1)k)
+ v2betabinomial(Ni,a2 = m2k, b2 = (1− m2)k)
+ vobetabinomial(Ni,ao = 1, bo = 1))
The more monosomic cells in the sample, the further
these two mixtures will separate (Fig. 2). The priors μ1 and
μ2, which are the average AAF of the two separated mixtures,
are determined by the fraction of aneuploidy cells, f. Given
the expected midpoint (calculated as average AAF for all het-
erozygous sites from the whole genome) m, the expected
mean AAF of the two mixtures (μ1, μ2) can be calculated as
m1 = m+
mf (1−m)
1− f +mf ;m2 = m−
mf (1−m)
1−mf
The hyperprior on f is modeled by a uniform beta distri-
bution, which means the fraction of abnormal cells ranges
from 0% to 100% with equal prior probability before
Kong et al.
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inference
f  beta(af = 1,bf = 1)
Thus, under this model, the likelihood of the data is
given by
P(AD|N,a,b) =
∏K
i=1
(v1dbetabinom(ADi,Ni,a1,b1)
+ v2dbetabinom(ADi,Ni,a2,b2)
+ vodbetabinom(ADi,Ni,ao,bo))
3. Model2: mosaic mitotic trisomy.Mosaicmitotic trisomy aris-
es from nondisjunction during mitotic cell division, result-
ing in an extra copy of one of the normal chromosomes.
As a result, the AAF at heterozygous sites will be separated
into two mixtures, in a qualitatively similar pattern to that
ofmosaicmonosomy case (Fig. 2). However, the expected av-
erage AAFs of the mixtures for a given fraction of aneuploidy
differ, with the means expected to be given by
m1 = m+
mf (1−m)
1+mf ;m2 = m−
mf (1−m)
1+ f −mf
The hyperprior f and the weights for separated mixtures
ω1 and ω2 and the outlier component are the same as de-
scribed in mosaic monosomy.
4. Model3: mosaic meiotic trisomy. Trisomy can also be ac-
quired during meiotic cell division. Mosaic meiotic trisomy
can be distinguished from mitotic trisomy by the presence
of two additional mixtures for part of the chromosome
near the boundaries (Fig. 2), which are the consequence of re-
combination during meiosis. Based on the assumption that
the four separated mixtures have the same variance (κ), the
allelic depth of heterozygous sites can be modeled as
ADi (v1betabinomial(Ni,a1 = m1k,b1 = (1− m1)k)
+ v2betabinomial(Ni,a2 = m2k,b2 = (1− m2)k)
+ v3betabinomial(Ni,a3 = m3k,b3 = (1− m3)k)
+ v4betabinomial(Ni,a4 = m4k,b4 = (1− m4)k)
+ v0betabinomial(Ni,a0 = 1,b0 = 1)
Among the four separatedmixtures, the twomixtures in
the center are expected to have the same means as described
in model2 (μ1, μ2). The means of the two additional mixtures
near the boundaries are given by
m3 =
mf
2+mf − 2m ;m4 = 1−
f (1−m)
f + 2m− fm
We assume that the two central mixtures have the same
weight and that the two edge mixtures also have the same
proportion. As the edge mixtures can have smaller or equal
weight compared to the center mixtures, we therefore model
the prior of the weight of the edge mixtures by a truncated
uniform beta distribution
v3  beta(a = 1,b = 1)I(0.1,0.25);
v1 = v2;v3 = v4;vo = 0.01;
v1 + v2 + v3 + v4 + vo = 1
The hyperprior f is modeled the same way as described
above.
5. Model4: mosaic loss of heterozygosity (LOH). Mosaic copy
number neutral loss of heterozygosity can be due tomultiple
reasons, for example, due to trisomy rescue when the whole
chromosome is involved, or recombination-mediated repair
when the LOH is segmental. As a result, the AAFs of the het-
erozygous sites or all or some of the chromosomewill also be
split into twomixtures (Fig. 2). To characterize such regional
effects of LOH, we introduced a reversible jump model,
which contains two change points (cgps, cgpe) to account
for the start and end of the LOH status, to describe the com-
bination of normal and abnormal regions on the same chro-
mosome.
In the normal regions, the model is the same as for a
normal chromosome
ADi v1betabinomial(Ni,a1=m1k,b1=(1−m1)k)
+vobetabinomial(Ni,ao= 1,bo=1); (i, cgps or i. cgpe)
In the LOH region, the distribution of AAFs is separated
into two mixtures:
ADi v2betabinomial(Ni,a2 = m2k,b1 = (1− m2)k)
+ v3betabinomial(Ni,a3 = m3k,b3 = (1− m3)k)
+ vobetabinomial(Ni,ao = 1,bo = 1); (cgps ≤ i ≤ cgpe)
For the normal region (i〈cgps or i〉cgpe), the distribution is
modeled in the same way as for a normal chromosome, with
μ1 calculated here as the average AAF for heterozygous sites.
For the LOH region, the weights for the two mixtures are as-
sumed to be the same. The means of the separated mixtures
are calculated as
m2 =
m(1+ f )
(1− f + 2mf ) ;m3 =
m(1− f )
( f − 2mf + 1)
The hyperprior f is modeled the same way as described
above.
Given that there is a total of K heterozygous sites on
each chromosome, the priors of the changing points, which
are the starting locus and ending locus of the abnormal re-
gion, are modeled by two uniform distributions ranging
from 1 to K. In order to be robust against noise in the data,
we require that the LOH region spans at least 10%of the total
number of loci (K) on one chromosome
cgps  uniform(1,0.90K);
cgpe  uniform(cgps + 0.10K,K)
2. Inference of the type of aneuploidy from sequencing depth.
While the distribution of AAF is informative of mosaic aneu-
ploidy, it is difficult to distinguish between the cases without addi-
tional information, as, for example, mitotic trisomy and mosaic
monosomy have similar distribution of AAFs. In order to improve
our differentiation of different types of aneuploidy, we augmented
our model with information about sequencing depth.
In ourmodel, the expected coverage for normal chromosome
is denoted bymg. If there is only one sample,mg is calculated as the
median of GC corrected coverage for the whole genome. If there
aremultiple samples,mg is calculated as themedian across the nor-
malized coverage for that chromosome across all samples.
For the sequencing depth, the total number of targeted re-
gions from one chromosome is nRegion; the coverage of the ith re-
gion is covi. In order to characterize the overdispersion of the depth
observed in massively parallel sequencing data, we model the
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coverage as a negative binomial distribution
covi  NegativeBinomial( prob = p, size = r)
where the prior of r is modeled by a weakly informative gamma
distribution
r  gamma(shape = 0.01, rate = 0.01)
and p is taken as
p = r
mcov + r
Here, mcov, which is the mean of the coverage for this chro-
mosome, is determined by the expected normal coverage mg
and the fraction of aneuploid cells f
mcov = mg (2+ f )2 (type = trisomy);
mcov = mg (2− f )2 (type = monosomy);
mcov = mg (type = normal or type = LOH)
In this way, we could further optimize the estimation for the
fraction f through the coverage information, while at the same
time better inferring the type of aneuploidy. The likelihood of
the coverage data over all sites is
P(cov|p, r) =
∏nRegion
i=1
NegativeBinomial(covi, prob = p, size = r)
To combine information from the AAF and coveragemodels,
we take the combined likelihood as
L = LAAF × LCov = P(Z|N,a,b) × P(cov|p, r)
MCMC sampling
Having the likelihood function and prior set for each model, the
posterior distribution is sampled through Markov Chain Monte
Carlo (MCMC). The sampling process is done using JAGS in the
R package rjags (https://cran.r-project.org/web/packages/rjags/
index.html). The script for the model is included in the
MADSEQ package at Bioconductor (see Supplemental Material).
For all the sample and computational simulation, we set the
burn-in steps to 10,000, and we sampled two chains, each with
a total of 10,000 steps and each step sampled at every two steps.
The convergence of the two chains is checked using the
Gelman and Rubin diagnostic with the coda package in R (https://
cran.r-project.org/web/packages/coda/index.html).
Model comparison
After we get the posterior distribution fromMCMC sampling, the
goodness of fit ofmodels is compared using the Bayesian informa-
tion criterion. The exact maximum likelihood of eachmodel can-
not be calculated directly from the MCMC procedure because of
the hierarchical nature of the model, so we take a point estimate
of the likelihood for eachmodel using the median of each param-
eter from the posterior distribution (Ntzoufras 2009).
Ultimately, the model with the lowest BIC is preferred as the
best model, and the type and fraction of aneuploidy are estimated
from the posterior distribution of the best model. If the ΔBIC be-
tween the selected model and other models is less than 10, then
we consider the chosen model to be low confidence.
Computational simulations
We aimed to evaluate the performance of ourmodel as a function
of sequencing depth, the type and fraction of aneuploidy cells,
and the number of heterozygous sites sequenced for one chromo-
some. We randomly generate data as follows:
1. Simulation of coverage. Given the expected normal cover-
age mcov and the fraction of the aneuploid cells f, the average
coverage for the chromosome mcov can be calculated as de-
scribed above. The sequencing depth covi for the i
th site was
randomly drawn from the negative binomial distribution
Covi  nbinom mcov, prob = mcovvarcov , r =
m2cov
varcov −mcov
( )
We set the variance of the coverage (varcov) to 30× mcov
based on what we observed from the actual sequencing data.
The total number of targeted regions (nRegions) was fixed as
1.5 times the total number of heterozygous sites (K).
2. Simulation of AAFs. Given the type of aneuploidy, the frac-
tion of abnormal cells ( f ), the total number of heterozygous
sites (K) on one chromosome, and themidpoint AAF (m) across
all heterozygous sites. The mean AAF for each mixture (µj) is
easily calculated using the formula described in the model sec-
tion. The weight for eachmixture (ωj) is given in the same way
as in the model; we randomly assigned ωjK sites into the j
th
mixture. Knowing the average coverage for the simulated chro-
mosome (mcov), the read depth for the i
th heterozygous site (Ni)
is also random drawn from the negative binomial distribution
Ni  nbinom mcov, prob = mcovvarcov , r =
mcov2
varcov −mcov
( )
The alternate allelic depth for the ith site (ADi) is randomly
generated from the binomial distribution as
ADij  binom(Nij, prob = mj)
3. Simulation of noise. To account for the influence of noise
in real sequencing data, we randomly selected 1% of the sites
to have an alternate allele frequency drawn from a uniform
beta distribution. We also randomly picked 1% of the regions
to have random coverage uniformly spanning from one read
to the maximum amount of coverage. When testing the false
positive rate, we increased the noise level to 10% instead.
Sincewe only use sites that are genotyped as heterozygous to
estimate the distribution of AAFs, we have to consider the capac-
ity of the genotyping algorithms to call heterozygous sites. In ge-
neral, genotyping algorithms will call a site as heterozygous if
there are multiple reads supporting each allele. We therefore fil-
tered out sites with fewer than three reads supporting both the al-
ternate and reference alleles and sites whose AAFs are less than
0.02 or greater than 0.98 from the simulated data. We simulated
500 sets of data for each aneuploidy scenario.
Exome sequencing data from the 1000 Genomes Project
The BAM files of exome sequencing data of 2535 individuals from
the 1000 Genomes Project were downloaded from the FTP site of
the 1000Genomes Project: ftp://ftp.1000genomes.ebi.ac.uk/. The
BED file containing the targets of the exome sequencing was
downloaded from: ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/
technical/reference/exome_pull_down_targets/.
Design of multi-ethnic targeted loci
We show the steps involved in Supplemental Figure S9.Genotyping
data of the 1000Genomes Project were downloaded from: http://ftp
.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/.
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First, we kept only biallelic loci. The heterozygosity rate for
each locus was then calculated as
heterozygosity rate = individuals genotyped as heterozygous
total number of individuals
Loci with a heterozygosity rate greater than 0.4 were retained.
Loci located in repetitive regions annotated by the RepeatMasker
(rmsk) track from the UCSC Genome Browser were excluded.
Loci located within ±20 bp of known indels and within ±500 bp
of gaps were excluded.We used the hg19 version of the human ge-
nome as this is the version used by Roche-NimbleGen for their
probe capture designs. In order to decrease (G +C) content bias,
we removed loci located within extreme (G +C) content regions
([G + C] < 0.3 or [G +C] > 0.65, 200 bp context).
According to the computational simulation, the model can
achieve very high sensitivity when there are ≥2000 heterozygous
sites sequenced on each chromosome. As themean heterozygosity
for the loci we retained was 0.45, we aimed to keep 5000 loci per
chromosome for the targeted sequencing.
In order to make loci evenly distributed along the chromo-
some instead of forming clusters, we binned each chromosome
into 500 equal-sized windows using BEDTools (Quinlan and Hall
2010). We then randomly selected ∼10 loci from each window.
In total, we created a list containing 105,703 commonSNPs for fur-
ther capture.We used a Q-Q plot to show that there was no cluster-
ing of loci compared to randomly selected loci.
Alignment, genotyping, and data processing
Raw FASTQ files from the sequencing were aligned to the GRCh37
human reference genome using BWA-MEM (v0.7.10) in default
paired-endmode (Li 2013). Picard (v1.119)was used tomark dupli-
cates, andGATK (v3.4-46) (McKenna et al. 2010) was used for indel
re-alignment and base recalibration following best practices.
HaplotypeCaller was used to call variants and to genotype all of
the targeted sites.
Estimation of ancestries of samples
We performed principal component analysis (PCA) using
EIGENSTRAT (Price et al. 2006) across 12 samples sequenced by
meMAD-seq assay and 2054 samples (26 populations) in the
1000 Genomes Project. SNPs used for PCA analysis are 1000G
SNPs located in the captured regions of the meMAD-seq assay.
VCFtools (Danecek et al. 2011) is used to process the SNPs.
MADSEQ model application
Having aligned the BAM file, genotyped the VCF file, and prepared
the BED file containing the targeted regions, we used theMADSEQ
package to correct for GC bias and filter noise, running
the MADSEQ model as described in the documentation on
Bioconductor.
Statistical analysis
We performed a binomial test and χ2 test to test enrichment and
association between detected aneuploidy and other factors. All
the statistical testing was performed in R (v3.2) (R Core Team
2012).
Software availability
The MADSEQ package is available from Bioconductor: http://
bioconductor.org/packages/MADSEQ/. MADSEQ source code is
also available in the Supplemental Material. The meMAD-seq
capture design is available from Roche-NimbleGen: Catalog
No. 067402 60001, Design Identifier: 160407_HG19_MadSeq_
EZ_HX1.
Data access
The deep sequencing data from the F44P110 and hemihyperplasia
patients from this study have been submitted to the NCBI
Database of Genes and Phenotypes (dbGaP; https://www.ncbi.
nlm.nih.gov/gap) under accession number phs001557.v1.p1.
The deep sequencing data from the v1MAD-seq and meMAD-seq
capture sequencing experiments from this study have been sub-
mitted to the NCBI Sequence Read Archive (SRA; https://www.
ncbi.nlm.nih.gov/sra) under accession number SRP105435 (sam-
ple numbers SRS2153291–SRS2153299).
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